LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has finalized agreements to place its exclusive MiQLab(TM) systems at two specialty and emergency veterinary hospitals as part of the company’s Early Access Program (“EAP”); the company anticipates placing the systems in early 2021. The two practices are Veterinary Specialty Hospital (“VSH”) of Palm Beach Gardens, Florida, and Denver Animal Emergency in Denver, North Carolina. According to the agreement, the two leading hospitals will evaluate MiQLab-generated data, which is generated quickly, against traditional culture and sensitivity testing, which can take up to five days to produce results. The difference in time that results are available can be vital when treating animals infected with multi-drug resistant pathogens. “We are very excited to be placing MiQLab systems at innovative veterinary hospitals like VSH and Denver,” said LexaGene founder and CEO Dr. Jack Regan in the press release. “We expect these systems to demonstrate the advantage of having in-house automated rapid testing for pathogens and antibiotic resistance markers, which is expected to improve patient care and clinical outcomes. The feedback we receive from these industry leading practices will help us in our efforts to gain wide adoption in this market.”
To view the full press release, visit https://ibn.fm/6rEve
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.
NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.